A look at the extraordinary safety record of the plasma industry's continuous supply of safe therapies at volume.
During the past three decades,IVIG has proven an effective treatment for a wide range of autoimmune diseases, and it is now believed that IVIG may have clinical uses for a broader range of medical conditions.
The current H1N1 pandemic exemplifies the need for more expeditious production of flu vaccine, and two companies have placed this technology just within reach.
Scientists around the world are working to improve upon and create new therapeutic options for hemophiliacs.
With the FDA approval of SCIG therapy in 2006, many patients now have the choice between SCIG and IVIG infusions. Understanding the differences between the two treatment modalities will help healthcare providers recommend the right one for their patients.
As plasma protein therapies evolve to satisfy the world’s demand, the volume and costs of the therapies produced is dictated by which of the therapies is in highest demand.
Today’s consumers rely on Internet research to self-diagnose everything from headaches to heart disease, and it’s a trend that has irrevocably altered the dynamic of traditional doctor-patient relations.
On the cutting edge of innovation in the biopharmaceuticals marketplace, manufacturers are developing new vaccines against diseases for which there is a critical need, as well as improving existing vaccines.
Unpredictable fluctuation in supply and demand, combined with the current reimbursement model, is the root of the problem of affordableIG treatment.
Average prices for albumin have remained steadily low, evading inflation and price increases for several decades.
This year’s flu season is shaping up to be one of the most challenging in history, with the new H1N1 (swine) strain adding to the questions and myths that already surround seasonal flu. Here are the facts.